DK2403878T3 - Cadm1-specifikke fuldt humane antistoffer - Google Patents
Cadm1-specifikke fuldt humane antistoffer Download PDFInfo
- Publication number
- DK2403878T3 DK2403878T3 DK10708470.9T DK10708470T DK2403878T3 DK 2403878 T3 DK2403878 T3 DK 2403878T3 DK 10708470 T DK10708470 T DK 10708470T DK 2403878 T3 DK2403878 T3 DK 2403878T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- cadm1
- seq
- human
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Isoleret monoklonalt antistof, eller antigenbindende del deraf, eller antistoffragment, der binder en epitop på humant CADM1 og omfatter en variabel tungkæderegion, der omfatter aminosyresekvensen ifølge SEQ ID NO: 19, 20, eller 21 og en variabel letkæderegion, der omfatter aminosyresekvensen ifølge SEQ ID NO: 22, 23 eller 24.
2. Isoleret monoklonalt antistof, eller antigenbindende del deraf, eller antistoffragment, der binder en epitop på humant CADM1 og som omfatter: (a) en variabel tungkæderegion CDR1, der omfatter SEQ ID NO: 1, en variabel tungkæderegion CDR2, der omfatter SEQ ID NO: 4, en variabel tungkæderegion CDR3, der omfatter SEQ ID NO: 7, en variabel letkæderegion CDR1, der omfatter SEQ ID NO: 10, en variabel letkæderegion CDR2, der omfatter SEQ ID NO: 13 og en variabel letkæderegion CDR3, der omfatter SEQ ID NO: 16; eller (b) en variabel tungkæderegion CDR1, der omfatter SEQ ID NO: 2, en variabel tungkæderegion CDR2, der omfatter SEQ ID NO: 5, en variabel tungkæderegion CDR3, der omfatter SEQ ID NO: 8, en variabel letkæderegion CDR1, der omfatter SEQ ID NO: 11, en variabel letkæderegion CDR2, der omfatter SEQ ID NO: 14 og en variabel letkæderegion CDR3, der omfatter SEQ ID NO: 17; eller (c) en variabel tungkæderegion CDR1, der omfatter SEQ ID NO: 3, en variabel tungkæderegion CDR2, der omfatter SEQ ID NO: 6, en variabel tungkæderegion CDR3, der omfatter SEQ ID NO: 9, en variabel letkæderegion CDR1, der omfatter SEQ ID NO: 12, en variabel letkæderegion CDR2, der omfatter SEQ ID NO: 15 og en variabel letkæderegion CDR3, der omfatter SEQ ID NO: 18.
3. Antistof ifølge krav 1 eller krav 2: (A) hvor antistoffet er er et fuldlængde antistof af en IgGl-, IgG2-, IgG3- eller IgG4-isotypc; (B) hvor antistoffet er udvalgt fra gruppen bestående af: et fuldt antistof, et antistoffragment, et humaniseret antistof, et humant antistof, et enkeltkædeantistof, et manipuleret antistof, der resulterer i øget binding til Fc-receptorer og/eller øget potens for ADCC, og et bispecifikt antistof; (C) hvor antistoffet, der er konjugeret til et terapeutisk middel, fortrinsvis hvor det terapeutiske middel er et cytotoksin eller en radioaktiv isotop; eller (D) hvor antistoffet binder til humant CADM1 med en EC50 i intervallet fra < 50 nM, fortrinsvis hvor antistoffet binder til humant CADM1 med en EC50 i intervallet fra < 10 nM, og mere fortrinsvis hvor antistoffet binder til humant CADM1 med en EC50 i intervallet fra < 1 nM.
4. Sammensætning, der omfatter det isolerede antistof, den antigenbindende del eller antistoffragmentet, der binder en epitop på humant CADM1 ifølge krav 1 eller krav 2, og en farmaceutisk acceptabel bærer.
5. Isoleret nukleinsyremolekyle, der koder for tung- eller letkæden af antistoffet eller den antigenbindende del eller antistoffragmentet, der binder en epitop på humant CADM1 ifølge krav 1 eller krav 2; eller en ekspressionsvektor, der omfatter nukleinsyremolekylet; eller en værtscelle, der omfatter ekspressionsvektoren.
6. Fremgangsmåde til fremstilling af et anti-CADMl-antistof, hvilken fremgangsmåde omfatter følgende trin: opnåelse af en værtscelle, der indeholder ét eller flere nukleinsyremolekyler, der koder for antistoffet ifølge krav 1 eller krav 2; dyrkning af værtscellen i en værtscellekultur; tilvejebringelse af værtsccllcdyrkningsbctingclscr, hvor det ene eller flere nukleinsyremolekyler udtrykkes; og genvinding af antistoffet fra værtscellen eller fra værtscellekulturen.
7. Isoleret monoklonalt antistof, eller antigenbindende del deraf, eller antistoffragment som defineret i krav 1 eller krav 2 til anvendelse i en fremgangsmåde til behandling eller forebyggelse af en sygdom forbundet med målceller, der udtrykker CADM1, fortrinsvis hvor sygdommen er en human cancer, og mere fortrinsvis hvor den humane cancer er udvalgt fra gruppen bestående af: småcellet lungecancer, T-celleleukæmi hos voksne, ikke-småcellet lungecancer (herunder pladeepitelkarcinomer og adenokarcinomer), melanom, brystcancer, colorektalcancer, ovariecancer, prostatacancer, neuroendokrine cancere, herunder cancere i lunge, binyre, hypofyse, mave-tarm-kanal, nyre, lever (herunder hepatocellulære karcinomer), pankreas (herunder insulinomer og glueagonomer), glioblastomer og carcinoide tumorer, herunder tumorer i pankreas, lunge, mave-tarm-kanal, lever og nyre.
8. Isoleret monoklonalt antistof eller antigenbindende del deraf, eller antistoffragment ifølge krav 1 eller krav 2, der binder en epitop på humant CADM1 og omfatter en variabel tungkæderegion og en variabel letkæderegion udvalgt fra gruppen bestående af: den variable tungkæderegions aminosyresekvens ifølge SEQ ID NO: 19 og den variable letkæderegions aminosyresekvens ifølge SEQ ID NO: 22; den variable tungkæderegions aminosyresekvens ifølge SEQ ID NO: 20 og den variable letkæderegions aminosyresekvens ifølge SEQ ID NO: 23; og den variable tungkæderegions aminosyresekvens ifølge SEQ ID NO: 21 og den variable letkæderegions aminosyresekvens ifølge SEQ ID NO: 24.
9. Isoleret antistof ifølge krav 8: hvor antistoffet er udvalgt fra gruppen bestående af: et fuldt antistof, antistoffragment, et humaniseret antistof, et humant antistof, et enkeltkædeantistof, et manipuleret antistof, der resulterer i øget binding til Fe-receptorer og/eller øget potens for ADCC, og et bispecifikt antistof.
10. Sammensætning, der omfatter det isolerede antistof eller den antigenbindende del deraf ifølge krav 8 og en farmaceutisk acceptabel bærer.
11. Isoleret nukleinsyremolekyle, der koder for tung- eller letkæden af det isolerede antistof eller den antigenbindende del deraf ifølge krav 8; eller en ekspressionsvektor, der omfatter nukleinsyremolekylet; eller en værtscelle, der omfatter ekspressionsvektoren.
12. Hybridom, der udtrykker antistoffet eller den antigenbindende del eller antistoffragmentet, der binder en epitop på humant CADM1 ifølge et hvilket som helst af kravene 1,2 eller 8.
13. Fremgangsmåde til fremstilling af antistoffet ifølge et hvilket som helst af kravene 1, 2 eller 8, der omfatter følgende trin: immunisering af et transgent dyr, der omfatter human immunoglobulingener med et CADM1-peptid; genvinding af B-celler fra det transgene dyr; frembringelse af hybridomer fra B-celleme; udvælgelse af hybridomer, der udtrykker antistoffer, der binder CADM1; og genvinding af antistofferne, der binder CADM1 ffa de udvalgte hybridomer.
14. Fremgangsmåde til fremstilling af anti-CADMl-antistoffer omfattende følgende trin: immunisering af et transgent dyr, der omfatter humane immunoglobulingener med et CADM1-peptid; genvinding af mRNA fra B-cellerne af det transgene dyr; omdannelse af mRNA’et til cDNA; ekspression af cDNA’et i phager, således at anti-CADMl-antistoffer, der er kodet for af cDNA’et, præsenteres på overfladen af phageme; udvælgelse af phager, der præsenterer anti-CADMl-antistoffer; genvinding af nukleinsyremolekyler fra de udvalgte phager, der koder for anti-CADMl-immunoglobulineme; ekspression af de genvundne nukleinsyremolekyler i en værtscelle; og genvinding af antistoffer som defineret i et hvilket som helst af kravene 1, 2 eller 8 ffa værtscellen, der binder CADM1.
15. Immunkonjugat, der omfatter (i) et isoleret antistof ifølge krav 8 eller krav 9 og (ii) et terapeutisk middel.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20939009P | 2009-03-05 | 2009-03-05 | |
US20947109P | 2009-03-05 | 2009-03-05 | |
PCT/US2010/026315 WO2010102175A1 (en) | 2009-03-05 | 2010-03-05 | Fully human antibodies specific to cadm1 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2403878T3 true DK2403878T3 (da) | 2017-09-18 |
Family
ID=42144944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10708470.9T DK2403878T3 (da) | 2009-03-05 | 2010-03-05 | Cadm1-specifikke fuldt humane antistoffer |
Country Status (25)
Country | Link |
---|---|
US (2) | US8420084B2 (da) |
EP (1) | EP2403878B1 (da) |
JP (1) | JP5816558B2 (da) |
KR (1) | KR101769160B1 (da) |
CN (1) | CN102341412B (da) |
AU (1) | AU2010221186B2 (da) |
BR (1) | BRPI1009232B1 (da) |
CA (1) | CA2753702C (da) |
CY (1) | CY1119539T1 (da) |
DK (1) | DK2403878T3 (da) |
EA (1) | EA028336B1 (da) |
ES (1) | ES2639026T3 (da) |
HR (1) | HRP20171274T1 (da) |
HU (1) | HUE034196T2 (da) |
IL (1) | IL214779A (da) |
LT (1) | LT2403878T (da) |
ME (1) | ME02842B (da) |
MX (1) | MX2011009220A (da) |
NZ (1) | NZ594682A (da) |
PL (1) | PL2403878T3 (da) |
PT (1) | PT2403878T (da) |
SG (1) | SG173742A1 (da) |
UA (1) | UA102891C2 (da) |
WO (1) | WO2010102175A1 (da) |
ZA (1) | ZA201105918B (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
DK2069793T3 (da) * | 2006-08-29 | 2017-04-24 | Oxford Biotherapeutics Ltd | Identifikation af protein i forbindelse med hepatocellulært karcinom, glioblastom og lungecancer |
EA028336B1 (ru) * | 2009-03-05 | 2017-11-30 | МЕДАРЕКС Л.Л.Си. | Полностью человеческие антитела, специфические в отношении cadm1 |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
CA2876517C (en) | 2012-07-19 | 2019-01-08 | Matthew Stuible | Anti-siglec-15 antibodies |
JP6440968B2 (ja) * | 2013-05-28 | 2018-12-19 | 国立大学法人 宮崎大学 | IgSF4/TSLC1/CADM1を特異的に認識できる抗体 |
US11208483B2 (en) * | 2015-11-19 | 2021-12-28 | Shanghai Kanda Biotechnology Co, Ltd. | CTLA-4 antibodies and uses thereof |
JP7229503B2 (ja) * | 2018-03-16 | 2023-02-28 | 国立大学法人 東京大学 | CADM1v9認識抗体 |
MX2021004588A (es) * | 2018-10-22 | 2022-01-18 | Shanghai Genbase Biotechnology Co Ltd | Anticuerpo anti-cldn18.2 y sus usos. |
WO2022239766A1 (ja) * | 2021-05-11 | 2022-11-17 | 国立大学法人 東京大学 | 抗cadm1抗体 |
TW202321296A (zh) * | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
KR20230061710A (ko) | 2021-10-29 | 2023-05-09 | 주식회사 이뮤노로지컬디자이닝랩 | Cadm1을 인식하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
KR20230062691A (ko) | 2021-10-29 | 2023-05-09 | 주식회사 이뮤노로지컬디자이닝랩 | Cadm1에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人t細胞白血病の治療又は予防のための医薬組成物 |
JP7270944B1 (ja) * | 2022-09-13 | 2023-05-11 | 学校法人近畿大学 | 抗cadm1抗体またはその抗原結合断片 |
Family Cites Families (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US5144011A (en) | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4698420A (en) | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5789157A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5864026A (en) | 1990-06-11 | 1999-01-26 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
US5763566A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
US5712375A (en) | 1990-06-11 | 1998-01-27 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JP3949712B2 (ja) | 1991-12-02 | 2007-07-25 | メディカル リサーチ カウンシル | 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生 |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
DE69633227T2 (de) | 1995-05-03 | 2005-09-15 | Gilead Sciences, Inc., Foster City | Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex |
US6548530B1 (en) | 1995-10-03 | 2003-04-15 | The Scripps Research Institute | CBI analogs of CC-1065 and the duocarmycins |
US6642360B2 (en) | 1997-12-03 | 2003-11-04 | Genentech, Inc. | Secreted polypeptides that stimulate release of proteoglycans from cartilage |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
AU754083B2 (en) | 1997-05-22 | 2002-11-07 | Scripps Research Institute, The | Analogs of duocarmycin and CC-1065 |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
JP2002505850A (ja) | 1997-12-03 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ポリペプチド及び同じものをコードしている核酸 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
CA2327457A1 (en) | 1998-05-07 | 1999-11-11 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
NZ510357A (en) | 1998-08-07 | 2004-02-27 | Immunex Corp | Molecules designated B7L-1 |
JP4426724B2 (ja) | 1998-08-07 | 2010-03-03 | イミュネックス・コーポレーション | Ldcamと称される分子 |
CA2348824A1 (en) | 1998-10-28 | 2000-05-25 | Human Genome Sciences, Inc. | 12 human secreted proteins |
US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
WO2000028032A2 (en) | 1998-11-12 | 2000-05-18 | Incyte Pharmaceuticals, Inc. | Human cell surface receptor proteins |
AU2474700A (en) | 1998-12-01 | 2000-06-19 | Genentech Inc. | Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
CA2361221A1 (en) | 1999-03-23 | 2000-09-28 | Genentech, Inc. | Novel protein which induces chondrocyte differentiation |
ES2569919T3 (es) | 1999-04-09 | 2016-05-13 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US7129338B1 (en) | 1999-07-08 | 2006-10-31 | Research Association For Biotechnology | Secretory protein or membrane protein |
US6387620B1 (en) | 1999-07-28 | 2002-05-14 | Gilead Sciences, Inc. | Transcription-free selex |
EP1210372B1 (en) | 1999-07-29 | 2008-01-23 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2002014577A1 (fr) * | 2000-08-04 | 2002-02-21 | Japan Lifeline Co., Ltd | Procede pour produire un element metallique cylindrique a paroi mince |
DE60136212D1 (de) | 2000-08-15 | 2008-11-27 | Univ Johns Hopkins Med | Diagnose und behandlung von tumor-suppressor assoziierten krankheiten |
EP1328636A2 (en) | 2000-09-01 | 2003-07-23 | Nuvelo Inc. | Nucleic acids and polypeptides |
JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
US20020157122A1 (en) * | 2000-10-27 | 2002-10-24 | Wong Philip C. | Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof |
WO2002066643A2 (en) | 2000-11-13 | 2002-08-29 | Curagen Corporation | Proteins, polynucleotides encoding them and methods of using the same |
TWI313299B (en) | 2000-11-30 | 2009-08-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
DE60227067D1 (de) | 2001-05-11 | 2008-07-24 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
CN101671335A (zh) | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | 细胞毒素、其有用的前体药物、连接基团和稳定剂 |
DE60239679D1 (de) | 2001-06-11 | 2011-05-19 | Medarex Inc | Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
CA2459308A1 (en) | 2001-09-07 | 2003-03-20 | Dale L. Boger | Cbi analogues of cc-1065 and the duocarmycins |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
PT1517921E (pt) | 2002-06-28 | 2006-09-29 | Domantis Ltd | Ligandos duplamente especificos com semi-vida no soro aumentada |
AU2003286004A1 (en) | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
CA2516128A1 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
EP1464709B1 (en) | 2003-03-31 | 2007-12-26 | Stichting Researchfonds Pathologie | Detection of HPV-induced invasive cancers and their precursor lesions with invasive potential |
DE10316701A1 (de) | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
DE602004025799D1 (de) | 2003-04-15 | 2010-04-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
EP2357237A1 (en) | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
WO2005012530A2 (en) | 2003-07-25 | 2005-02-10 | Amgen Inc. | Antagonists and agonists of ldcam and methods of use |
US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
JP4227881B2 (ja) | 2003-11-13 | 2009-02-18 | 財団法人宮崎県産業支援財団 | 成人t細胞白血病診断薬 |
AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
CA2564076C (en) | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2006049854A2 (en) | 2004-10-29 | 2006-05-11 | Genentech, Inc. | Disruptions of genes encoding secreted proteins, compositions and methods relating thereto |
CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
AU2006216291B2 (en) * | 2005-02-27 | 2011-01-27 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
JP4536588B2 (ja) * | 2005-05-11 | 2010-09-01 | 財団法人宮崎県産業支援財団 | 成人t細胞白血病の診断器具 |
US7842467B1 (en) | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
JP5131946B2 (ja) | 2005-09-13 | 2013-01-30 | 国立大学法人 東京大学 | がんの診断、処置および/または予防、および/または浸潤・転移の抑制のための方法、システムおよび組成物ならびに関連するスクリーニング方法 |
EA016577B1 (ru) | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Конъюгаты антитело-лекарство и их применение |
CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
KR20080068084A (ko) | 2005-10-26 | 2008-07-22 | 메다렉스, 인코포레이티드 | 씨씨-1065 유사체를 제조하기 위한 방법 및 화합물 |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
JP5525729B2 (ja) | 2005-11-28 | 2014-06-18 | ゲンマブ エー/エス | 組換え一価抗体およびその作製方法 |
JP5131751B2 (ja) | 2005-12-28 | 2013-01-30 | 国立大学法人 東京大学 | 小細胞肺がんの診断のための方法、システムおよび組成物ならびに関連するスクリーニング方法 |
US7842291B1 (en) | 2006-05-22 | 2010-11-30 | Celera Corporation | Methods and compositions for diagnosing and treating diseases |
WO2008007648A1 (fr) | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
EP2520935A3 (en) | 2006-08-09 | 2013-02-13 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
DK2069793T3 (da) * | 2006-08-29 | 2017-04-24 | Oxford Biotherapeutics Ltd | Identifikation af protein i forbindelse med hepatocellulært karcinom, glioblastom og lungecancer |
AU2007325931A1 (en) | 2006-11-02 | 2008-06-05 | Yale University | Assessment of oocyte competence |
EP1918299A1 (en) | 2006-11-03 | 2008-05-07 | Universite De Geneve | Modulators of cell adhesion molecules and use thereof |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
US20100330558A1 (en) | 2007-04-06 | 2010-12-30 | Bankaitis-Davis Danute M | Gene Expression Profiling for Identification, Monitoring and Treatment of Cervical Cancer |
WO2008142693A2 (en) | 2007-05-22 | 2008-11-27 | Yeda Research And Development Co. Ltd. | Regulation of myelination by nectin-like (necl) molecules |
DK2185933T3 (da) * | 2007-08-07 | 2015-10-26 | Oxford Biotherapeutics Ltd | Matriptaseprotein og anvendelser deraf |
KR20100067089A (ko) | 2007-08-30 | 2010-06-18 | 제넨테크, 인크. | T 세포를 조정하기 위한 방법 및 조성물 |
WO2009040782A2 (en) | 2007-09-28 | 2009-04-02 | Royal College Of Surgeons In Ireland | A method of assessing colorectal cancer status in an individual |
EP2128259A1 (en) | 2008-05-27 | 2009-12-02 | Koninklijke Philips Electronics N.V. | Therapy delivery and monitoring using a gene of interest-reporter fusion protein and optical imaging |
AU2010208394A1 (en) | 2009-01-27 | 2011-09-08 | Hologic, Inc. | Biomarkers for detection of neonatal sepsis in biological fluid |
EA028336B1 (ru) | 2009-03-05 | 2017-11-30 | МЕДАРЕКС Л.Л.Си. | Полностью человеческие антитела, специфические в отношении cadm1 |
-
2010
- 2010-03-05 EA EA201101242A patent/EA028336B1/ru unknown
- 2010-03-05 AU AU2010221186A patent/AU2010221186B2/en active Active
- 2010-03-05 PT PT107084709T patent/PT2403878T/pt unknown
- 2010-03-05 UA UAA201111731A patent/UA102891C2/uk unknown
- 2010-03-05 CN CN201080010338.5A patent/CN102341412B/zh active Active
- 2010-03-05 LT LTEP10708470.9T patent/LT2403878T/lt unknown
- 2010-03-05 NZ NZ594682A patent/NZ594682A/xx unknown
- 2010-03-05 BR BRPI1009232-3A patent/BRPI1009232B1/pt active IP Right Grant
- 2010-03-05 JP JP2011553127A patent/JP5816558B2/ja active Active
- 2010-03-05 KR KR1020117023235A patent/KR101769160B1/ko active IP Right Grant
- 2010-03-05 DK DK10708470.9T patent/DK2403878T3/da active
- 2010-03-05 SG SG2011059292A patent/SG173742A1/en unknown
- 2010-03-05 WO PCT/US2010/026315 patent/WO2010102175A1/en active Application Filing
- 2010-03-05 ME MEP-2017-194A patent/ME02842B/me unknown
- 2010-03-05 ES ES10708470T patent/ES2639026T3/es active Active
- 2010-03-05 MX MX2011009220A patent/MX2011009220A/es active IP Right Grant
- 2010-03-05 CA CA2753702A patent/CA2753702C/en active Active
- 2010-03-05 HU HUE10708470A patent/HUE034196T2/en unknown
- 2010-03-05 EP EP10708470.9A patent/EP2403878B1/en active Active
- 2010-03-05 PL PL10708470T patent/PL2403878T3/pl unknown
- 2010-03-05 US US13/254,752 patent/US8420084B2/en active Active
-
2011
- 2011-08-12 ZA ZA2011/05918A patent/ZA201105918B/en unknown
- 2011-08-22 IL IL214779A patent/IL214779A/en active IP Right Grant
-
2012
- 2012-12-27 US US13/728,059 patent/US20130156788A1/en not_active Abandoned
-
2017
- 2017-08-22 HR HRP20171274TT patent/HRP20171274T1/hr unknown
- 2017-08-29 CY CY20171100907T patent/CY1119539T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2403878T3 (da) | Cadm1-specifikke fuldt humane antistoffer | |
AU2008308956B2 (en) | Human antibodies that bind mesothelin, and uses thereof | |
US9217033B2 (en) | Monoclonal antibodies against Glypican-3 | |
MX2008006792A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |